Gastrointestinal-specific multiple drug release system

Abstract

The present invention provides compositions and methods for the multiple release of a drug in the gastrointestinal tract of a subject through the use of an oral multiple drug release system. The system provides site-specific release of the drug to both the small intestine and the colon in the form of multiple controlled doses for long-lasting efficacy, thereby reducing the drug dosing frequency.

1 . An oral multiple drug release composition, said composition comprising:
 (a) a drug core comprising a first drug and a saccharide;   (b) an organic acid-soluble polymer, wherein said drug core is coated by said organic acid-soluble polymer;   (c) a drug layer comprising a second drug, wherein said organic acid-soluble polymer is coated by said drug layer;   (d) a water-permeable, release-controlling polymer, wherein said drug layer is coated by said water-permeable, release-controlling polymer; and   (e) an enteric coat comprising an enteric coating polymer, wherein said water-permeable, release-controlling polymer is coated by said enteric coat,   
     wherein said composition releases said second drug in the small intestine and said first drug in the colon. 
   
   
       2 . The composition of  claim 1 , wherein said drug core comprises a mixture of said first drug and said saccharide. 
   
   
       3 . The composition of  claim 1 , wherein said first drug is coated by said saccharide. 
   
   
       4 . The composition of  claim 3 , further comprising a water-permeable, release-controlling polymer as a layer in between said first drug and said saccharide, admixed with said first drug, or a combination thereof. 
   
   
       5 . The composition of  claim 1 , wherein said first drug and said second drug are the same drug. 
   
   
       6 . The composition of  claim 1 , wherein said first drug and said second drug are different drugs. 
   
   
       7 . The composition of  claim 1 , wherein said first drug is a combination of at least two drugs. 
   
   
       8 . The composition of  claim 1 , wherein said first drug and said second drug are independently selected from the group consisting of a proton pump inhibitor, a peptide, a protein, a hormone, an anti-inflammatory agent, an antitussive expectorant, a vasodilator, an analgesic, a histamine H 2 -receptor antagonist, an antibiotic, an antiepileptic agent, an antigout agent, an antitumor agent, an antidiabetic agent, an antipsychotic agent, a prostatomegaly agent, an antiasthma agent, a drug with a short pharmacokinetic half-life, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof. 
   
   
       9 . The composition of  claim 8 , wherein said proton pump inhibitor is selected from the group consisting of omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof. 
   
   
       10 . The composition of  claim 1 , wherein said drug core further comprises a buffering agent. 
   
   
       11 . The composition of  claim 1 , wherein said drug layer further comprises a buffering agent. 
   
   
       12 . The composition of  claim 1 , wherein said saccharide is selected from the group consisting of lactulose, raffinose, cellobiose, stachyose, fructoligosaccharide, sucrose, glucose, xylose, fructose, mannitol, maltose, galactose, and combinations thereof. 
   
   
       13 . The composition of  claim 12 , wherein said saccharide is lactulose. 
   
   
       14 . The composition of  claim 12 , wherein said saccharide is present in an amount of from about 10% to about 90% w/w. 
   
   
       15 . The composition of  claim 1 , wherein said organic acid-soluble polymer is selected from the group consisting of a dimethylaminoethyl methacrylate-methyl methacrylate copolymer, a polyvinyl acetal diethylaminoacetate, chitosan, and combinations thereof. 
   
   
       16 . The composition of  claim 15 , wherein said dimethylaminoethyl methacrylate-methyl methacrylate copolymer is a dimethylaminoethyl methacrylate-methyl methacrylate-butyl methacrylate copolymer. 
   
   
       17 . The composition of  claim 15 , wherein said organic acid-soluble polymer is present in an amount of from about 2.5% to about 40.0% w/w. 
   
   
       18 . The composition of  claim 15 , wherein said organic acid-soluble polymer dissolves at a pH lower than about 6. 
   
   
       19 . The composition of  claim 1 , wherein said water-permeable, release-controlling polymer is selected from the group consisting of a copolymer of ethyl acrylate, methyl methyacrylate, and trimethylammonioethyl methacrylate chloride, ethyl cellulose, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose, polyethylene oxide, polyvinylpyrrolidone, and combinations thereof. 
   
   
       20 . The composition of  claim 19 , wherein said water-permeable, release-controlling polymer is HPMC. 
   
   
       21 . The composition of  claim 1 , wherein said enteric coating polymer is selected from the group consisting of a methyl methacrylate-methylacrylate acid (1:1) copolymer, a methyl methacrylate-methacrylate acid (2:1) copolymer, an ethyl acrylate-methacrylic acid (1:1) copolymer, hydroxypropylmethylcellulose phthalate, cellulose acetate phthalate, shellac, and combinations thereof. 
   
   
       22 . The composition of  claim 1 , wherein said enteric coat comprises a mixture of said enteric coating polymer and a third drug. 
   
   
       23 . The composition of  claim 1 , further comprising an outer drug coat having a third drug, wherein said enteric coat is coated by said outer drug coat and said composition releases said third drug in the stomach. 
   
   
       24 . The composition of  claim 1 , wherein said composition is in the form of a tablet or granule. 
   
   
       25 . The composition of  claim 1 , wherein said drug core comprises a mixture of a first proton pump inhibitor and lactulose, said organic acid-soluble polymer is a dimethylaminoethyl methacrylate-methyl methacrylate-butyl methacrylate copolymer, said drug layer comprises a second proton pump inhibitor, said water-permeable, release-controlling polymer is HPMC, and said enteric coat comprises an enteric coating polymer. 
   
   
       26 . An oral multiple drug release composition, said composition comprising:
 a first component, said first component comprising:
 (a) a drug core comprising a first drug; 
 (b) a water-permeable, release-controlling polymer, wherein said drug core is coated by said water-permeable, release-controlling polymer; and 
 (c) an enteric coat comprising an enteric coating polymer, wherein said water-permeable, release-controlling polymer is coated by said enteric coat; and 
   a second component, said second component comprising:
 (a) a drug core comprising a second drug and a saccharide; 
 (b) an organic acid-soluble polymer, wherein said drug core is coated by said organic acid-soluble polymer; and 
 (c) an enteric coat comprising an enteric coating polymer, wherein said organic acid-soluble polymer is coated by said enteric coat, 
   
     wherein said first component releases said first drug in the small intestine and said second component releases said second drug in the colon. 
   
   
       27 . The composition of  claim 26 , wherein said first and second components are inside a capsule. 
   
   
       28 . The composition of  claim 26 , wherein said drug core in said second component comprises a mixture of said second drug and said saccharide. 
   
   
       29 . The composition of  claim 26 , wherein said second drug is coated by said saccharide. 
   
   
       30 . The composition of  claim 29 , further comprising a water-permeable, release-controlling polymer as a layer in between said second drug and said saccharide, admixed with said second drug, or a combination thereof. 
   
   
       31 . The composition of  claim 26 , wherein said second component further comprises a water-permeable, release-controlling polymer, and wherein said organic acid-soluble polymer is coated by said water-permeable, release-controlling polymer 
   
   
       32 . The composition of  claim 26 , wherein said first drug and said second drug are the same drug. 
   
   
       33 . The composition of  claim 26 , wherein said first drug and said second drug are different drugs. 
   
   
       34 . The composition of  claim 26 , wherein said second drug is a combination of at least two drugs. 
   
   
       35 . The composition of  claim 26 , wherein said first drug and said second drug are independently selected from the group consisting of a proton pump inhibitor, a peptide, a protein, a hormone, an anti-inflammatory agent, an antitussive expectorant, a vasodilator, an analgesic, a histamine H 2 -receptor antagonist, an antibiotic, an antiepileptic agent, an antigout agent, an antitumor agent, an antidiabetic agent, an antipsychotic agent, a prostatomegaly agent, an antiasthma agent, a drug with a short pharmacokinetic half-life, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof. 
   
   
       36 . The composition of  claim 35 , wherein said proton pump inhibitor is selected from the group consisting of omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof. 
   
   
       37 . The composition of  claim 26 , wherein said drug core in said first component further comprises a buffering agent. 
   
   
       38 . The composition of  claim 26 , wherein said drug core in said second component further comprises a buffering agent. 
   
   
       39 . The composition of  claim 26 , wherein said saccharide is selected from the group consisting of lactulose, raffinose, cellobiose, stachyose, fructoligosaccharide, sucrose, glucose, xylose, fructose, mannitol, maltose, galactose, and combinations thereof. 
   
   
       40 . The composition of  claim 39 , wherein said saccharide is lactulose. 
   
   
       41 . The composition of  claim 39 , wherein said saccharide is present in an amount of from about 10% to about 90% w/w. 
   
   
       42 . The composition of  claim 26 , wherein said organic acid-soluble polymer is selected from the group consisting of a dimethylaminoethyl methacrylate-methyl methacrylate copolymer, a polyvinyl acetal diethylaminoacetate, chitosan, and combinations thereof. 
   
   
       43 . The composition of  claim 42 , wherein said dimethylaminoethyl methacrylate-methyl methacrylate copolymer is a dimethylaminoethyl methacrylate-methyl methacrylate-butyl methacrylate copolymer. 
   
   
       44 . The composition of  claim 42 , wherein said organic acid-soluble polymer is present in an amount of from about 2.5% to about 40.0% w/w. 
   
   
       45 . The composition of  claim 42 , wherein said organic acid-soluble polymer dissolves at a pH lower than about 6. 
   
   
       46 . The composition of  claim 26 , wherein said water-permeable, release-controlling polymer is selected from the group consisting of a copolymer of ethyl acrylate, methyl methyacrylate, and trimethylammonioethyl methacrylate chloride, ethyl cellulose, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose, polyethylene oxide, polyvinylpyrrolidone, and combinations thereof. 
   
   
       47 . The composition of  claim 46 , wherein said water-permeable, release-controlling polymer is HPMC. 
   
   
       48 . The composition of  claim 26 , wherein said enteric coating polymer is selected from the group consisting of a methyl methacrylate-methylacrylate acid (1:1) copolymer, a methyl methacrylate-methacrylate acid (2:1) copolymer, an ethyl acrylate-methacrylic acid (1:1) copolymer, hydroxypropylmethylcellulose phthalate, cellulose acetate phthalate, shellac, and combinations thereof. 
   
   
       49 . The composition of  claim 26 , wherein said enteric coat in said second component comprises a mixture of said enteric coating polymer and a third drug. 
   
   
       50 . The composition of  claim 26 , wherein said first component, second component, or a combination thereof further comprises an outer drug coat having a third drug, wherein said enteric coat is coated by said outer drug coat and said composition releases said third drug in the stomach.